Does prehospital thrombolysis increase the proportion of patients who have an aborted myocardial infarction?

Emergency Medicine Journal

Volumn 26, Issue 3, 2009, Pages 206-209

  Jackson, L ^a,d   Kendall, J ^b   Castle, N ^c  

^a BRISTOL ROYAL INFIRMARY   (United Kingdom)

^b FRENCHAY HOSPITAL   (United Kingdom)

^c FRIMLEY PARK HOSPITAL   (United Kingdom)

^d QUEEN MARGARET HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CREATINE KINASE; TROPONIN I;

ARTICLE; BLOOD CLOT LYSIS; CLINICAL FEATURE; CONTROLLED STUDY; EMERGENCY CARE; HEART INFARCTION; HOSPITAL CARE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; REPERFUSION; ST SEGMENT ELEVATION; TREATMENT OUTCOME; UNITED KINGDOM;

AGED; CHI-SQUARE DISTRIBUTION; CORONARY DISEASE; ELECTROCARDIOGRAPHY; EMERGENCY MEDICAL SERVICES; EMERGENCY TREATMENT; GREAT BRITAIN; HOSPITALIZATION; HUMANS; MIDDLE AGED; MYOCARDIAL INFARCTION; RETROSPECTIVE STUDIES; THROMBOLYTIC THERAPY; TIME FACTORS; TREATMENT OUTCOME; TROPONIN;

EID: 61749103745     PISSN: 14720205     EISSN: 14720213     Source Type: Journal    
DOI: 10.1136/emj.2008.061564     Document Type: Article

References (25)

1. Department of Health. Report on death registrations in England and Wales, 2004: causes. Health Statistics Quarterly 2005;26:64-8.
2. Gruppo Italiano per lo Studio della Streptochinase nell' Infarto miocardio (GISSI). Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet 1986;1:397-402.
3. Second International Study of Infarct Survival Collaborative Group (ISIS-2). Randomized trial of intravenous streptokinase, oral aspirin, both or neither among 17187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988;2:349-60.
4. Wilcox RG, Olsson CG, Skene AM, et al. Trial of tissue plasminogen activator for mortality reduction in acute myocardial infarction: Anglo-Scandinavian Study of Early Thrombolysis (ASSET). Lancet 1988;2:525-30.
5. Tebbe U, Carlsson J. Prehospital thrombolytic therapy for acute myocardial infarction. Herz 1994;6:303-13.
6. Huber K, De Caterina R, Kristensen SD, et al. Prehospital reperfusion therapy: a strategy to improve therapeutic outcome in patients with ST-elevation myocardial infarction. Eur Heart J 2005;26:2063-74.
7. Lamfers EJP, Hooghoudt TEH. Benefit of Pre-hospital thrombolysis in the treatment of acute myocardial infarction. Ned Tijdschr Geneeskd 2000;144:514-8.
8. Taher T, Fu Y, Wagner GS, et al. Aborted myocardial infarction in patients with STelevation: insights from the ASSENT-3 ECG substudy. J Am Coll Cardiol 2004;44:38-43.
9. Rawles JM. Quantification of the benefit of earlier thrombolytic therapy: five-year results of the Grampian Region Early Anistreplase Trial (GREAT). J Am Coll Cardiol 1997;30:1181-6.
10. Yuling F, Goodman S, Chang W, et al. Time to treatment influences the impact of ST-segment resolution on one-year prognosis: insights from the Assessment of the Safety and Efficacy of a New Thrombolytic (ASSENT-2) Trial. Circulation 2001;104:2653-9.
11. Weaver WD, Cerquiera M, Hallstrom AP, et al. Prehospital-initiated vs hospital-initated thrombolytic therapy. The Myocardial Infarct Triage and Intervention Trial. JAMA 1993;270:1211-6.
12. Lamfers EJP, Hooghoudt TEH, Uppelschoten A, et al. Effect of prehospital thrombolysis on aborting acute myocardial infarction. Am J Cardiol 1999;84:928-30.
13. Verheugt FWA, Bernard JG, Armstrong PW. Aborted myocardial infarction: a new target for reperfusion therapy. Eur Heart J 2006;27:901-4.
14. Scottish Intercollegiate Guidelines Network. Acute coronary syndromes: a national clinical guideline. 2007;93:1-2.
15. Fox KAA, Birkhead J, Wilcox R, et al. British Cardiac Society Working Group on the definition of myocardial infarction. Heart 2004;90:603-9.
16. Lamfers EJP, Hooghoudt TEH, Hertzberger DP, et al. Abortion of acute ST segment elevation myocardial infarction after reperfusion: incidence, patients' characteristics and prognosis. Heart 2003;89:496-501.
17. Lamfers EJP, Schut A, Hertzberger DP, et al. Prehospital versus hospital fibrinolytic therapy using automated versus cardiologist electrographic diagnosis of myocardial infarction: abortion of myocardial infarction and unjustified fibrinolytic therapy. Am Heart J 2004;147:509-15.
18. Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 Investigators. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomissed trial in acute myocardial infarction. Lancet 2001;358:605-13.
19. Dowdy L, Wagner GS, Birnbaum Y, et al. Aborted infarct: the ultimate myocardial salvage. Am Heart J 2004;147:390-4.
20. Boersma E, Maas ACP, Deckers JW, et al. Early thrombolytic treatment in acute myocardial infarction: reappraisal of the golden hour. Lancet 1996;348:771-5.
21. Morrison LJ, Verbeek PR, McDonald AC, et al. Mortality and prehospital thrombolysis for acute myocardial infarction: a meta-analysis. JAMA 2000;283:2686-92.
22. Trent R, Adams J, Rawles J. Electrocardiographic evidence of reperfusion occurring before hospital admission. A Grampian Region Early Anistreplase Trial (GREAT) sub-study. Eur Heart J 1994;15:895-7.
23. Widimsky P, Budesinsky T, Vorac D, et al. Long distance transport for primary angioplasty vs immediate thrombolysis in acute myocardial infarction. Final results of the randomized national multicentre trial: PRAGUE-2. Eur Heart J 2003;24:94-104.
24. Steg PG, Bonnefoy E, Chabaud S, et al. Impact of time to treatment on mortality after prehospital fibrinolysis or primary angioplasty: data from the CAPTIM randomized clinical trial. Circulation 2003;108:2581-6.
25. West Steering Committee. A comparison of pharmacological therapy with/without timely coronary intervention v primary percutaneous intervention early after ST-segment myocardial infarction. Eur Heart J 2006;27:1530-8.